Kesimpta ® is reimbursed in Belgium for adult patients with clinically proven relapsing multiple sclerosis (RMS) who meet the following criteria* :
The patient has a fast evolving, serious form of relapsing multiple sclerosis (RMS...
B-cells play a central role in the pathogenesis of MS 4
KESIMPTA ® (ofatumumab) is a fully human anti...
FABHALTA ® is indicated as monotherapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) who have haemolytic anemia 1 .
FABHALTA® is the first and only Factor B inhibitor. FABHALTA® acts...
The efficacy and safety 5 of iptacopan in adult patients with PNH were evaluated in two multicentre, open-label, 24-week phase III studies: an active comparator-controlled study (...
Mechanism of Action (MoA)¹
Iptacopan is a proximal complement inhibitor that targets Factor B (FB) to selectively inhibit the alternative pathway of the complement cascade. Inhibition of FB in the...
Dosing¹
Posology & Method of AdministrationThe recommended dose is 200 mg taken orally twice daily.
Healthcare professionals should advise patients with PNH about the...